Lumonall Inc. Form 10QSB November 14, 2007

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC. 20549

FORM 10-QSB

[X]	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
	1934.

For the Quarterly Period Ended September 30, 2007

[]	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
	1934.

For the transition period from to	
-----------------------------------	--

Commission File No. 0-28315

LUMONALL, INC.

(Exact Name of Small Business Issuer as Specified in Its Charter)

MIDLAND INTERNATIONAL CORPORATION

(Former name of corporation if changed since last report)

Nevada 84-1517404
(State or Other Jurisdiction Employer of Incorporation) Identification No.)

3565 King Road, Suite 102 King City, Ontario, Canada L7B 1M3 (Address of Principal Executive Offices) (905) 833-9845

(Issuer's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of

Edgar Filing: Lumonall Inc. - Form 10QSB

the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes[X] No[]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [No[X]]

As of November 9, 2007, the number of common stock outstanding was 107,917,654

Lumonall, Inc. (A Development Stage Company)

INDEX

PART I	Financial Information	
Item 1.	Condensed Financial Statements (unaudited) Condensed Balance Sheet Condensed Statements of Operations Statements of Change in Stockholders' Deficiency Condensed Statements of Cash Flows Notes to Condensed Financial Statements	3 2 5 7
Item 2.	Management's Discussion and Analysis	15
Item 3.	Controls and Procedures	20
PART II.	Other Information	21
Item 1.	<u>Legal</u> <u>Proceedings</u>	21
Item 2.	<u>Unregistered Sales of Equity Securities and Use of</u> <u>Proceeds</u>	21
Item 3.	Defaults Upon Senior Securities	21
Item 4.	Submission of Matters to a Vote of Security Holders	21
Item 5.	Other Information	21
Item 6.	Exhibits A) Exhibit 31.1 B) Exhibit 31.2 C) Exhibit 32.1 D) Exhibit 32.2	22
<u>Signatures</u>		23

PART I. Financial Information

Item 1. Condensed Financial Statements

Lumonall, Inc.
(A Development Stage Company)
Condensed Balance Sheet
September 30, 2007
(UNAUDITED)

ASSETS

Current Assets:		
Cash and cash equivalents	\$	55,614
Due from related parties (Note 4)		169,744
Prepaid expenses		11,382
Total current assets		236,740
Investment (Note 5)		99,377
Intangibles (Note 6)		90,000
TOTAL ASSETS	\$	426,117
LIABILITIES AND STOCKHOLDERS' DEFICIENCY		
Current Liabilities:		
Accounts payable and accrued liabilities	\$	174,260
Due to related parties (Note 4)		145,080
Deposits		190,000
Note payable - related parties (Note 7)		50,000
Total current liabilities		559,340
Stockholders' deficiency		
Preferred stock, \$0.001 par value, 5,000,000 shares authorized, No shares		
issued and outstanding		-
Common stock, \$0.001 par value, 200,000,000 shares authorized,		
107,917,654 shares issued and outstanding at Sept. 30, 2007		107,918
Additional paid-in capital		2,554,873
Accumulated deficit	()	2,796,014)
Total stockholders' deficiency		(133,223)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	\$	426,117

See accompanying notes to financial statements.

Lumonall, Inc.
(A Development Stage Company)
Condensed Statements of Operations
(UNAUDITED)

		Three mon		30		Six mont		er 30	(I	ay 1, 1996 nception) to eptember 30 2007
Revenues	\$	2007	\$	2006	\$	2007	\$	2006	\$	60,000
revenues	Ψ		Ψ		Ψ		Ψ		Ψ	00,000
Cost of sales		-		-		-		-		49,500
Gross profit		-		-		-		-		10,500
Operating expenses:										
Management fees		55,000		-		115,000		-		925,585
Office and general		102,920		7,702		344,351		9,429		699,061
Professional and consulting		386,125		17,500		538,415		63,927		1,096,771
Amortization		5,000		-		10,000		-		10,050
Total operating expenses		549,045		25,202		1,007,766		73,356		2,731,467
Net loss before other expenses and		(5.40, 0.45)		(25, 202)		(1.007.766)		(50.056)		(2.720.067)
income taxes		(549,045)		(25,202)		(1,007,766)		(73,356)		(2,720,967)
Other expenses										
Share of loss of equity accounted										
investee		_		_		623		_		623
Interest expense		_		8,564		-		17,317		34,421
Realized loss on disposal of assets		_		-		_		-		10,003
Write off of intangible assets		_		_		_		_		30,000
Total other expenses		-		8,564		623		17,317		75,047
•				,				,		,
Net loss before income taxes		(549,045)		(33,766)		(1,008,839)		(90,673)	((2,796,014)
Provision for income taxes		-		-		-		-		-
Net loss	\$	(549,045)	\$	(33,766)	\$	(1,008,839)	\$	(90,673)	\$	(2,796,014)
Weighted average number of common										
shares outstanding – Basic and diluted		101,529,176		33,417,654		98,329,348		33,408,327	2	23,465,740
Loss per share of common stock - Basic		(0.00=	,.	(0.04=:		(0.015)		(0.005)	4	(0.110)
and diluted	\$	(0.005)	\$	(0.010)	\$	(0.010)	\$	(0.003)	\$	(0.119)

Edgar Filing: Lumonall Inc. - Form 10QSB

See accompanying notes to financial statements.

4

Lumonall, Inc. (A Development Stage Company) Statement of Change in Stockholders' Deficiency May 1, 1996 to March 31, 2007 (UNAUDITED)

Common Stock

	Common	Amount	Additional Paid-in Capital	Accumulated Income (Deficit)	Total Stockholders' Deficiency
Balance, May 1, 1996	-	\$ -	-	-	-
Issuance of common stock	24,000,000	24,000	(23,700)	-	300
Net loss for the period from inception to March 31, 2004	-	-	-	(19,186)	(19,186)
Balance, March 31, 2004	24,000,000	\$ 24,000	(23,700)	(19,186)	(18,886)
Exchange of debt for equity	-	-	30,500	-	30,500
Shares issued as consideration for assets purchased	3,000,000	3,000	71,503	-	74,503
Common stock issued for services	78,000	78	59,922	-	60,000
Issuance of common stock pursuant to private placements	1,250,000	1,250	213,750	-	215,000
Common stock issued for consulting services provided	650,000	650	64,350	-	65,000
Net loss for the year ended March 31, 2005	-	-	-	(558,404)	(558,404)
Balance, March 31, 2005	28,978,000	\$ 28,978	416,325	(577,590)	(132,287)
Issuance of common stock pursuant to cash received in prior period	900,000	900	(900)	-	_
Issuance of common stock pursuant to private placements	600,000	600	59,400	-	60,000
	350,000	350	64,650	-	65,000

Edgar Filing: Lumonall Inc. - Form 10QSB

Common stock issued for consulting services provided					
Issuance of common stock pursuant to private placements	2,400,000	2,400	100,297	-	102,697
Cash received for shares issued after year end	-	-	8,060	-	8,060
Net loss for the period ended March 31, 2006 Balance, March 31, 2006	33,228,000	\$ 33,228	647,832	(894,850) (1,472,440)	(894,850) (791,380)
Common stock issued for cash received before year end	189,654	190	(190)	-	_
Issuance of common stock pursuant to private placements	2,000,000	2,000	83,811	-	85,811
Issuance of common stock pursuant to private placements	2,700,000	2,700	132,300	-	135,000
Issuance of common stock pursuant to investment	20,000,000	20,000	80,000	-	100,000
Issuance of common stock pursuant to debt forgiveness	27,750,000	27,750	377,400	-	405,150
Net loss for the year ended March 31, 2007	-	-	-	(315,185)	(315,185)
Balance, March 31, 2007	85,867,654	85,868	1,321,153	(1,787,625)	(380,604)

See accompanying notes to financial statements.

5

Lumonall, Inc.
(A Development Stage Company)
Condensed Statement of Change in Stockholders' Deficiency
April 1, 2007 to September 30, 2007
(UNAUDITED)

Common Stock

	Shares	A	Amount	Additional Paid-in Capital	Common Stock Subscribed	Accumulated Income (Deficit)	Total Stockholders' Equity/
Balance, March 31, 2007	85,867,654	\$	85,868	1,321,153	-	(1,787,625)	(380,604)
Common stock subscriptions received	-		-	-	634,000	-	634,000
Issuance of common stock pursuant to private placements	7,680,000		7,680	376,320	(384,000)	-	-
Issuance of common stock for consulting services	2,700,000		2,700	132,300	-	-	135,000
Issuance of common stock pursuant to debt forgiveness	2,450,000		2,450	33,320	-	-	35,770
Net loss for the period ended June 30, 2007	-		-	-	-	(459,344)	(459,344)
Balance, June 30, 2007	98,697,654	\$	98,698	1,863,093	250,000	(2,246,969)	(35,178)
Issuance of common stock pursuant to private placements	9,220,000		9,220	451,780	(250,000)	-	211,000
Issuance of common stock purchase warrants	-		-	240,000	-	-	240,000
Net loss for the period ended September 30, 2007	-		-	-	-	(549,045)	(549,045)
Balance, September 30, 2007	107,917,654	\$	107,918	2,554,873	-	(2,796,014)	(133,223)

See accompanying notes to financial statements.

Lumonall, Inc. (A Development Stage Company) Condensed Statements of Cash Flows (UNAUDITED)

	Six Months I September 2007		May 1, 1996 (Inception) to September 30, 2007
Net cash used in operations			
Net loss	\$(1,008,389) \$	(90,673)	\$ (2,796,014)
Adjustments to reconcile net loss			
to net cash used in operating activities:			
Amortization	10,000	-	10,050
Share of loss of equity accounted investee	623	-	623
Loss on disposal of capital asset	-	-	10,003
Writedown of intangible assets	-	-	30,000
Bad debt expense	-	-	60,000
Common stock for consulting services provided	135,000	-	295,250
Warrants issued for consulting services provided	240,000	-	240,000
Changes in operating assets and liabilities:			
Accounts receivable	-	-	(60,000)
Inventory	-	-	49,500
& #160			